Articles tagged with Thrombosis
Researchers found in situ pulmonary artery thrombosis associated with radiation therapy has unique imaging characteristics and does not typically embolize. The study identified 27 patients with PAT after RT, highlighting the importance of radiologist awareness for accurate diagnosis and management.
A systematic review found that hospitalized COVID-19 patients have a high risk of developing venous thromboembolism (VTE), with ICU patients at the highest risk. The study estimated that up to 28% of critically ill patients may develop deep vein thrombosis or pulmonary embolism.
Researchers aim to enroll patients aged 6-17 with moderate to severe PANS and evaluate the effectiveness of PANZYGA versus placebo in reducing symptoms. The study will also assess sustainability and functional impairment associated with PANS treatment.
Researchers at Uppsala University found that a key mechanism of clot formation in COVID-19 may be activation of the complement system, triggered by elevated mannose-binding lectin (MBL) levels and activity. MBL can contribute to a massive activation of the blood coagulation system, resulting in thrombosis.
A new analysis found that cerebral venous thrombosis (CVT) incidence has increased three times higher than previously reported in the US. CVT is most common in younger women, but recent findings suggest increases in men and older women, with a notable disparity in Black people compared to other racial and ethnic groups.
A patient with COVID-19 developed late drug-eluting stent thrombosis, a serious cardiovascular complication. The case report highlights the need for careful monitoring and management of patients with COVID-19 to prevent such adverse events.
Patients with high disease activity in rheumatoid arthritis are at a higher risk of developing venous thromboembolism. Treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) such as TNF inhibitors can reduce this risk by nearly half compared to conventional synthetic drugs.
A case series reports a high incidence of deep vein thrombosis among critically ill patients with COVID-19. The study highlights the need for prompt recognition and treatment of this potentially life-threatening complication in ICU patients with severe SARS-CoV-2 infection.
The FDA approved a phase 3 clinical trial to evaluate the efficacy and safety of high-dose Octagam 10% therapy in COVID-19 patients with severe disease progression. The study aims to determine if IVIG can slow or stop respiratory deterioration in these patients.
Researchers developed a miniature human vein device called Vein-Chip to study changes in vein wall cells and blood flow that lead to DVT. The technology allows for testing various factors such as gender and ethnicity to predict DVT risk, paving the way for personalized therapies.
A new study led by University of Kentucky researcher Sidney Whiteheart aims to understand how platelets function in hemostasis and during immune responses. The research may lead to therapies to regulate platelet activation and lessen the risk of cardiovascular disease in patients with HIV1/AIDS or COVID-19.
Recent reports show a strong association between elevated D-dimer levels and poor prognosis in patients with COVID-19. Microvascular thrombotic processes may play a role in respiratory failure, suggesting a new severe infectious lung disease with no proven therapies.
A new approach to interpreting D-dimer blood tests can help rule out pulmonary embolism and reduce the need for CT scans, freeing up resources and reducing radiation exposure. The study found that a higher-than-usual D-dimer level can be considered a negative result in patients with low probability of having a pulmonary embolism.
Researchers Keefe Manning and Yong Wang propose a new method of surface modification of nanoparticles for local drug delivery to prevent thrombosis in medical devices. The goal is to develop a solution that would reduce side effects and increase drug concentration without frequent administration of antithrombotic drugs.
Researchers at Michigan Medicine discovered a previously unrecognized link between inflammation and deep vein thrombosis, finding that blocking a key inflammatory molecule reduced clot formation in mice.
A Marshall University researcher has been awarded a nearly $500,000 NIH grant to investigate the role of thymidine phosphorylase in thrombosis. The study aims to clarify the pathways mediating TYMP-enhanced platelet activation and establish pharmacological inhibition as a novel anti-thrombotic therapy.
Researchers developed a new approach using ultrasonic registration of blood coagulation in its early stages to prevent thrombosis. The technique involves continuous monitoring of the blood's aggregate state and automatic injection of fibrinolytic drugs, allowing for fast and complete dissolution of formed fibrin clots.
Researchers created platelet decoys that prevent blood clots and combat cancer spread, offering a promising new therapy. The fast-reversible approach could one day treat life-threatening bleeding in emergencies or surgical settings.
Researchers developed a new dielectric blood coagulometry (DBCM) method to assess Factor Xa (FXa) activity in patients treated with FXa inhibitors. The study showed that DBCM detected FXa inhibitor-specific changes in a manner similar to more complicated methods, offering a promising easy-to-use clinical treatment option.
Researchers discover that newborns have a unique state of balance in haemostasis, making them more prone to thrombosis and bleeding. The study found significant differences between the haemostasis of adults and infants, particularly in preterm babies.
A 16-year Danish cohort study found comparable risks of recurrence between patients with unprovoked and cancer-related venous thromboembolism. The cumulative incidence of recurrence after incident VTE was over 15% in all groups, highlighting the need for revised risk stratification approaches.
A Stanford-led study found a link between height and varicose veins, identifying 30 genes linked to the condition and suggesting that genetic markers of height may predict disease. The researchers used machine learning combined with epidemiological methods to examine genomic data on over 400,000 people.
UAB researchers develop potential therapy for TTP, a rare and deadly blood-clotting disorder, by delivering ADAMTS13 enzyme via platelets. The treatment inhibits thrombus formation in human and mouse blood, showing therapeutic benefit.
Researchers found that immediate compression therapy significantly reduced the risk of residual vein occlusion and post thrombotic syndrome in patients with DVT. The study suggests that starting compression therapy within 24 hours of diagnosis can prevent debilitating complications.
Research led by LSU Health found that hypoxia decreases Protein S, a natural anticoagulant, increasing the risk of potentially life-threatening blood clots. The study identified the gene regulatory mechanism controlling PS production in response to oxygen levels.
A new study lengthens intervals between blood draws for stable warfarin patients, reducing frequency and discomfort. Researchers found that more than two-thirds of patients can wait longer than five weeks without needing a blood draw.
Researchers used Blood Vessel-Chip to model and predict thrombosis induced by anti-CD154 monoclonal antibody, demonstrating its potential for safety testing and efficacy assessment. The chip recreated key parameters of thrombosis and provided insights into the mechanisms and biomarkers involved.
Researchers found a potential link between varicose veins and deep venous thrombosis, but more research is needed to confirm the association. The study also suggests that varicose veins may be associated with an increased risk of peripheral artery disease and pulmonary embolism.
A recent study published in the Journal of Thrombosis and Thrombolysis found that prolonged TV viewing increases the risk of venous thromboembolism, a potentially fatal condition. The research, which analyzed data from over 15,000 Americans, suggests that even regular exercise is not enough to offset the risks of sedentary behavior.
A new study by Boston University researchers confirms the link between chronic kidney disease and increased risk of blood clots, identifying specific tryptophan metabolites as key players. The findings provide a promising approach for risk stratification and potential treatment strategies for CKD patients.
Researchers discovered synthetic APC-mimicking small molecules called 'parmodulins' provide anti-inflammatory and anti-thrombotic protection on par with APC, but without interfering with blood clotting. Parmodulins activate PAR1, triggering protective pathways in endothelial cells.
A large clinical trial shows that clot-busting drugs do not prevent post-thrombotic syndrome, a complication that can cause chronic limb pain and swelling. The procedure did reduce the severity of the syndrome, but with an increased risk of major bleeding.
General practitioners trained in compression ultrasonography achieve excellent accuracy in diagnosing deep vein thrombosis, with a diagnostic accuracy of 96%. The technique's sensitivity and specificity rates are comparable to those of expert physicians.
The ABSORB IV trial found that biosorbable stents are non-inferior to traditional metal stents, but still require further advancements in device technology and technique. The study demonstrated a lower rate of device thrombosis with improved pre-dilatation and post-dilatation techniques.
A study found low public awareness of atrial fibrillation (AF), with only 48% globally aware, but 82% correctly identifying palpitations as an AF symptom. The estimated 33.5 million people worldwide live with AF, highlighting the need for increased public health initiatives.
A study by the American College of Physicians found that almost 11 million US men have oral human papillomavirus (HPV) infection, with a high prevalence among men with multiple lifetime oral sex partners and those who report having sex with men. HPV causes various cancers, including oropharyngeal squamous cell carcinoma, which dispropo...
The RESPECT trial found that closing a small hole in the heart reduced stroke recurrence by 45% compared to standard therapy. The study suggests this device is a good option for certain patients facing years of ongoing stroke risk, but may not be suitable for everyone.
Researchers have created a human pulmonary thrombosis model on a chip, allowing for the study of blood clot formation in the lung. The Thrombosis-on-a-Chip technology replicates human lung capillaries and perfuses whole human blood through it, enabling the testing of potential drugs to treat or prevent pulmonary thrombosis.
The CLUE Working Group conducted two systematic reviews to address thrombosis and hemorrhage risks after urological cancer operations and other forms of urological surgery. The studies found that anticoagulant prophylaxis is justified in high-risk patients, but not necessarily in low-risk procedures.
A large observational study found that CT scans detect subclinical leaflet thrombosis in 12.1% of patients after aortic valve replacement, increasing the risk of transient ischemic attacks but not death or stroke. Oral anticoagulants reduced the risk of clots, while anti-platelet therapy was associated with increased risk.
Researchers discovered that blocking IL-6 in psoriasis patients may not prevent skin inflammation, but its levels are central to thrombosis events triggered by skin inflammation. A compensatory 'workaround' mechanism involving other immune system molecules is proposed to explain the findings.
The American Society of Hematology announced top trainee abstracts from the 2016 ASH Annual Meeting, showcasing innovative research in hematology and stem cells. The awards recognize excellence in various categories, including undergraduate students, medical students, and postdoctoral fellows.
A national initiative prioritized research on venous thrombosis (VTE) in cancer patients, citing a 20% prevalence rate and increased risk with chemotherapy. The study identified key areas for future research, including platelet contributions to VTE and the impact of cancer therapies on blood cells.
Researchers found that microRNA-181b targets Card10, a protein that helps activate inflammation. In preclinical studies, the delivery of miR-181b reduced blood clot formation and prolonged time to artery blockage by up to 1.6 fold.
A recent study published in JAMA Neurology found that obese women who use oral contraceptives are at a higher risk for cerebral venous thrombosis (CVT), a rare and potentially life-threatening condition. The study also suggests that alternative methods of contraception, such as intrauterine devices, may be safer options for obese women.
Recent studies have analyzed trends in blood clot formation in patients with heart-assist devices, revealing a potential decline in thrombosis rates since 2011. However, the exact impact of this trend on patient outcomes remains unclear, and experts emphasize the need for continued vigilance and research.
Researchers identified how Salmonella infections trigger thrombosis through inflammation regulation and platelet activation. Thrombosis persisted even after bacteria were cleared from the blood, highlighting a previously unknown pathway involved in sepsis complications.
The new guideline aims to standardize the management of iliofemoral deep vein thrombosis (DVT) in Canada, providing a practical approach for physicians. The guideline recommends anticoagulants for all patients with DVT, as well as clot removal and compression therapy for those at high risk of bleeding.
The American College of Physicians released a guide for appropriate use of peripherally inserted central catheters (PICCs) to address growing concerns over their use in hospitals. The guide highlights the potential for complications like thrombosis and infection, as well as variation in their use among patients.
The study found that immune cell-mediated thrombotic processes are a realistic target for novel therapies to prevent stent thrombosis. Leukocyte infiltrations were hallmarks of both early and late ST, with neutrophils being the most prominent subset.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.
A large registry study found that patients experiencing stent thrombosis between 2-30 days post-procedure had higher mortality rates compared to those who developed the complication within 24 hours. The timing of stent thrombosis may be linked to more severe infarction and long-term heart failure.
A study of 11,648 patients found that extended dual antiplatelet therapy after bare metal stent placement did not significantly increase rates of stent thrombosis or major adverse cardiac and cerebrovascular events. However, the sample size limitations may have impacted the results, suggesting further trials are needed.
The European Society of Cardiology publishes first recommendations on new oral anticoagulants for pulmonary embolism. The guidelines provide detailed recommendations on drug use and risk stratification, including age-adjusted D-dimer cut-offs.
A study of 90,618 patients with DVT found CDT increased adverse events and hospital charges without significant impact on mortality rates. Patients treated with CDT had more blood transfusions, pulmonary embolism, and vena cava filter placement.
Patients with a history of stroke are at higher risk for major adverse cardiovascular events and death after elective non-cardiac surgery. A recent study found that the time elapsed between stroke and surgery is critical in determining this risk, with those experiencing a stroke less than 9 months prior being particularly vulnerable.
Researchers at Case Western Reserve University found that existing cancer treatment bortezomib increases levels of the vascular-protective gene KLF2, preventing blood clot formation. This discovery has potential implications for managing thrombosis in patients with predispositions to clot formation.
A new study suggests that a simple urine test can detect blood clots in patients at risk, offering advantages over existing screening methods. The test evaluates fibrinopeptide B levels in urine, which are released when a thrombosis forms and then cleared by the body.
The CHAMPION PHOENIX trial found cangrelor significantly reduces stent thrombosis (ST) at 48 hours and 30 days, associated with lower mortality. Cangrelor also improves freedom from ST at 30 days in various categories of ST.
After delivering a baby, women's blood clot risk remains higher than normal for at least 12 weeks due to increased platelets and other blood-clotting factors during pregnancy. Researchers found the risk decreased over time.